Buccal Mucosal Formulation Permeation and Absorption Testing: In Vitro and Ex Vivo Evaluation of Ora

Buccal mucosal formulation permeation and absorption testing evaluates how effectively active ingredients diffuse across the oral mucosa from mucoadhesive tablets, films, gels, and patches. Using Franz diffusion cells and ex vivo porcine buccal mucosa, accredited third-party laboratories quantify drug release rates, transmucosal flux, and permeability coefficients that predict in vivo performance. This article explains the technical principles, sample types, test parameters, methodologies, and applications of buccal absorption testing for pharmaceutical development and regulatory submission.

Technical Overview

Buccal drug delivery administers active pharmaceutical ingredients (APIs) through the mucosal lining of the inner cheek. Because this tissue is non-keratinized, richly vascularized, and bypasses both gastrointestinal degradation and hepatic first-pass metabolism, it enables rapid systemic uptake or effective local action. Buccal formulation permeation testing, often referred to as transmucosal absorption testing, is the laboratory study that measures how quickly and how completely an API is released from its dosage form and transported across the buccal membrane.

The buccal mucosa consists of a stratified squamous non-keratinized epithelium approximately 500 to 600 micrometers thick, a basement membrane, and a connective lamina propria. The principal permeability barrier lies within the epithelial intercellular lipid domains. Drug transport across this barrier occurs predominantly by passive diffusion via transcellular and paracellular routes, with optimal permeation generally observed for molecules of moderate lipophilicity (log P of approximately 1 to 3) and molecular weight below 500 to 1000 Daltons. Compared with human skin, the buccal mucosa can be several orders of magnitude more permeable, which makes dedicated transmucosal test protocols—rather than conventional transdermal skin protocols—essential for meaningful data.

The objectives of buccal permeation testing include characterizing drug release kinetics, quantifying steady-state flux and permeability coefficients, ranking candidate formulations, evaluating penetration enhancers, and generating supporting data for regulatory submissions and bioequivalence assessments.

Testing Samples

Buccal Tablets and Lozenges

Mucoadhesive compressed tablets and molded lozenges designed to dissolve or erode slowly against the cheek lining. These solid dosage forms are tested for both drug release behavior and transmucosal permeation of the liberated API.

Buccal Films and Wafers

Thin polymeric films and fast-dissolving wafers, typically 50 to 500 micrometers thick, prepared from film-forming polymers such as hydroxypropyl methylcellulose, polyvinyl alcohol, or chitosan. Permeation testing verifies that the API diffuses out of the hydrated matrix and crosses the mucosal barrier.

Buccal Gels, Ointments, and Semisolids

Mucoadhesive semisolid systems based on carbomer, sodium alginate, or cellulose derivatives. Testing determines release rate, residence behavior under simulated saliva flow, and mucosal transport.

Buccal Patches and Matrix Systems

Reservoir or matrix-type patches with drug-containing layers and optional rate-controlling membranes. Permeation studies confirm controlled delivery profiles and backing-membrane impermeability.

Solutions, Sprays, and Nanocarrier Systems

Buccal sprays, mouthwash-type solutions, liposomes, micelles, and nanoparticulate carriers. Testing quantifies mucosal uptake and any enhancement provided by nanoscale delivery vehicles.

Model Membranes

The biological barrier most commonly used is freshly excised porcine buccal mucosa, selected for its histological and permeability similarity to human tissue. Bovine, canine, rabbit, and ovine buccal mucosa are alternative models, while human tissue from consented surgical sources is used when available. Synthetic membranes, including regenerated cellulose, mixed cellulose esters, and silicone sheets, are employed for in vitro release testing where no biological barrier function is required.

Testing Items

Core parameters reported in a buccal absorption test program include:

• Cumulative amount of drug permeated per unit area (Q, in micrograms per square centimeter) as a function of time
• Steady-state flux (Jss, in micrograms per square centimeter per hour), obtained from the linear portion of the cumulative permeation curve
• Permeability coefficient (Kp) and apparent permeability (Papp), calculated by normalizing flux to donor drug concentration
• Lag time (Tlag), the x-axis intercept of the steady-state regression line, reflecting membrane loading and diffusion equilibration
• Enhancement ratio (ER), comparing flux with and without penetration enhancers
• Drug retained within the mucosal tissue after the test, determined by tissue extraction and assay
• In vitro release rate and release kinetics (zero-order, first-order, Higuchi, or Korsmeyer–Peppas modeling)
• Mass balance and recovery across membrane, receptor medium, donor compartment, and tissue, typically targeted within 85 to 115 percent
• Supporting characterization such as mucoadhesive strength, swelling index, surface pH, residence time, content uniformity, and assay of the dosage form itself

All quantitative determinations are performed using analytically validated methods, typically high-performance liquid chromatography (HPLC), UPLC, or LC-MS/MS, with validation characteristics meeting ICH Q2(R2) requirements for specificity, linearity, accuracy, precision, and quantitation limits.

Testing Methods

Vertical Franz Diffusion Cell Method

The standard platform for buccal permeation testing is the vertical Franz diffusion cell. The excised mucosal membrane, or an appropriate synthetic membrane for release studies, is mounted between the donor and receptor compartments with the epithelial surface facing the donor side. The dosage form is applied to the donor chamber, frequently under a layer of simulated saliva (phosphate buffer at pH 6.8) to mimic the oral environment. The receptor compartment is filled with phosphate-buffered saline (pH 6.8 to 7.4), sometimes containing a small percentage of solubilizer such as polysorbate 80 or sodium lauryl sulfate solely to maintain sink conditions. The receptor medium is held at 35 to 37 degrees Celsius with constant magnetic stirring. Aliquots are withdrawn at predetermined intervals—for example 0.5, 1, 2, 4, 6, 8, and up to 24 hours—and replaced with equal volumes of fresh pre-warmed medium to maintain constant volume. Samples are analyzed by validated chromatographic methods.

Ex Vivo Mucosa Preparation

Porcine buccal mucosa is obtained from freshly slaughtered animals at abattoirs and transported in cold oxygenated Krebs-Ringer buffer. Submucosal connective tissue and muscle are removed by careful surgical dissection, and the tissue is trimmed to a uniform thickness, typically 500 to 700 micrometers. Membrane integrity is verified visually and, where required, by electrical resistance measurement or barrier-marker permeability before the experiment. Tissue is used within 24 hours of excision when maintained under refrigerated isotonic conditions, or after validated cryopreservation with suitable cryoprotectants.

Side-by-Side (Ussing-Type) Chamber Method

For studies requiring metabolically active mucosa, horizontal side-by-side diffusion chambers are used. Both half-cells are perfused with oxygenated, glucose-supplemented buffer, and tissue viability is monitored continuously through electrophysiological parameters such as transmucosal electrical resistance and potential difference. This configuration supports carrier-mediated and metabolically influenced transport investigations.

In Vitro Release Testing (IVRT) versus In Vitro Permeation Testing (IVPT)

IVRT uses inert synthetic membranes to characterize drug liberation from the dosage form, following principles aligned with USP general chapters for semisolid performance testing. IVPT uses viable or freshly excised biological mucosa to characterize barrier-limited transport and predict mucosal absorption. A complete evaluation program typically includes both studies.

Data Analysis and Reporting

Cumulative permeation is plotted against time and corrected for sampling dilution. The steady-state flux is determined by linear regression of the linear region, generally requiring a coefficient of determination of at least 0.98 to 0.99. Kp is derived from flux divided by donor concentration, lag time from the regression intercept, and enhancement ratio from comparative flux values. Experiments are performed with a minimum of three to six replicates per group, and results are compared statistically using analysis of variance or appropriate paired tests. Methodological quality follows the general principles of OECD Test Guideline 428 adapted to oral mucosa, including membrane integrity verification, sink condition confirmation, and full mass-balance accountability. Studies are conducted under GLP-compliant protocols by ISO/IEC 17025-accredited third-party laboratories where regulatory submission is intended.

Applications

Buccal permeation and absorption data support a broad range of pharmaceutical development and regulatory activities:

• Formulation screening and optimization, including polymer grade selection, plasticizer level, and drug loading
• Ranking and justification of penetration enhancers such as bile salts, cyclodextrins, chitosan, menthol, and nonionic surfactants through enhancement ratio studies
• Comparative IVPT studies supporting bioequivalence demonstrations for generic buccally administered products
• Chemistry, manufacturing, and controls (CMC) documentation and regulatory submission packages for new drug applications
• Stability programs tracking permeation performance through shelf-life and post-approval changes
• Quality control batch release testing for release-rate specifications
• Research into peptide, protein, and vaccine buccal delivery, mucoadhesive nanocarriers, and transport mechanism elucidation
• Investigation of formulation factors affecting local versus systemic delivery targets

FAQ

Why is porcine buccal mucosa the preferred test membrane?

Porcine buccal mucosa is non-keratinized like human buccal tissue and exhibits comparable epithelial thickness, lipid composition, histology, and permeability characteristics. It is readily available from abattoirs, reduces reliance on laboratory animals, and has extensive literature precedent supporting correlation with human absorption.

How long does a typical permeation experiment run?

Most Franz cell experiments run 4 to 24 hours, depending on the dosage form. Fast-dissolving films may complete permeation within 4 to 8 hours, while sustained-release matrix systems may require the full 24-hour period with terminal tissue extraction.

What are the key acceptance criteria for a valid study?

A valid study demonstrates verified membrane integrity before and after testing, maintained sink conditions throughout, steady-state regression with adequate linearity, replicate reproducibility within predefined limits, and total mass balance typically between 85 and 115 percent of the applied dose.

What is the difference between IVRT and IVPT?

IVRT measures drug release from the dosage form through an inert synthetic membrane and reflects formulation release behavior. IVPT measures transport across an excised biological mucosa and additionally captures barrier-limited permeation, providing data more predictive of mucosal absorption.

Can human buccal mucosa be used for testing?

Yes, human tissue obtained from consented surgical procedures provides the most direct model, but availability, tissue size, and ethical approvals limit routine use. Porcine mucosa remains the standard practical substitute, with results supported by cross-species correlation data.

How do in vitro permeation results relate to in vivo absorption?

Flux and permeability values support formulation ranking, enhancer justification, and mechanistic understanding, and can be developed into in vitro–in vivo correlations. Definitive confirmation of systemic exposure, however, requires clinical pharmacokinetic studies.

Which standards and guidelines govern these studies?

Method design draws on the general principles of OECD Test Guideline 428 for in vitro absorption studies adapted to oral mucosa, analytical methods are validated per ICH Q2(R2), release performance testing follows USP general chapter principles, and laboratory competence is commonly demonstrated through ISO/IEC 17025 accreditation.